Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Fineline Cube Dec 16, 2025
Company Deals

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials

Fineline Cube Dec 16, 2025
Company Deals

Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option

Fineline Cube Dec 16, 2025
Company Deals

Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis

Fineline Cube Dec 16, 2025
Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025
Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Fineline Cube Dec 16, 2025
Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Fineline Cube Dec 16, 2025
Company Drug

Sanofi’s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans

Fineline Cube Dec 16, 2025
Policy / Regulatory

VBP Round 7 Drug Procurement Contract Awards Top Winners Revealed

Fineline Cube Jul 18, 2022

China’s 7th national Volume-Based Procurement (VBP) round concluded with winning bids for 60 drug products...

Company

Merck KGaA Launches Uptune Program in Asia, Offers Startups Up to €100,000

Fineline Cube Jul 18, 2022

Germany-based life sciences giant Merck KGaA has launched the Uptune program in Asia, offering up...

Company Drug

Pfizer Launches Cejemly in China for Stage III NSCLC, Expands Immunotherapy Reach

Fineline Cube Jul 18, 2022

Pfizer announced the commercial launch of Cejemly (sugemalimab) in China for Stage III non-small cell...

Company Deals

Sihuan Pharma to Sell Generic Drug Businesses, Shift Focus to Aesthetics and Biologics

Fineline Cube Jul 18, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced plans to divest a portion of...

Company Drug

Luye Pharma’s Lurbinectedin Receives Hainan Approval for SCLC Treatment

Fineline Cube Jul 18, 2022

China-based Luye Pharma Group (HKG: 2186) announced approval from the Hainan Medical Products Administration for...

Company Drug

Novartis’ Aimovig Launches in China via GBA Early Access Scheme for Migraine Treatment

Fineline Cube Jul 15, 2022

Swiss pharma giant Novartis’ (NYSE: NVS) migraine therapy Aimovig (erenumab) was administered for the first...

Drug

CStone Pharmaceuticals’ Gavreto Wins Hong Kong Approval for RET Fusion NSCLC

Fineline Cube Jul 15, 2022

CStone Pharmaceuticals (HKG: 2616) announced that its RET inhibitor Gavreto (pralsetinib) has received marketing approval...

Company Medical Device

NMPA Approves RocketHeart’s LV Assist System and Our United Group’s Radiation Therapy Device

Fineline Cube Jul 15, 2022

The National Medical Products Administration (NMPA) has approved marketing for two innovative medical devices: RocketHeart’s...

Company Deals Digital

Ping An Good Doctor Partners with China Biotech Services for Cancer Testing and BNCT Treatment

Fineline Cube Jul 15, 2022

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...

Company Drug

Kelun Pharma’s SKB264 ADC Receives NMPA Green Light for Phase II Solid Tumor Study

Fineline Cube Jul 15, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that its antibody drug conjugate (ADC)...

Company Drug

Luye Pharma Initiates Phase III Study of Trulicity Biosimilar BA5101 in China

Fineline Cube Jul 15, 2022

China-based Luye Pharma Group (HKG: 2186) announced the initiation of a Phase III clinical study...

Company Deals

Shanghai Electric and Siemens Partner on Localization of High-End Medical Equipment

Fineline Cube Jul 15, 2022

China’s Shanghai Electric Group has partnered with Germany-based Siemens Healthineers to localize high-end medical equipment,...

Company Drug

Beijing Science Sun’s LZ901 Shingles Vaccine Receives FDA IND Approval

Fineline Cube Jul 15, 2022

China-based Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced that its subsidiary Beijing Luzhu...

Company Deals

Ningbo HicRen Biotech Completes RMB100M Pre-Series C Financing for Orthopedic Robots

Fineline Cube Jul 15, 2022

Ningbo HicRen Biotechnology Co., Ltd, a China-based robotics-driven minimally invasive orthopedics platform, announced the completion...

Company Deals

CStone Pharmaceuticals Explores Strategic Options Including Buyout

Fineline Cube Jul 15, 2022

China-based CStone Pharmaceuticals (HKG: 2616) is evaluating strategic options, including a potential buyout, according to...

Drug

BeiGene’s Tislelizumab Faces FDA Delay Due to Inspection Hurdles

Fineline Cube Jul 15, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced a delay in the U.S. FDA’s decision...

Company Deals Drug

Frontier Biotech and Asymchem Partner on COVID-19 Drug FB2001 Development

Fineline Cube Jul 15, 2022

China-based Frontier Biotechnologies Inc. (SHE: 200342) announced a strategic partnership with Asymchem Laboratories (Tianjin) Co.,...

Company Medical Device

Acotec Scientific’s AcoArt Orchid & Dhalia DCB Wins China Approval for AVF PTA

Fineline Cube Jul 14, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that its AcoArt Orchid & Dhalia DCB,...

Company Deals

Orion Holdings to Build Jining Vaccine Plant in China’s Shandong Province

Fineline Cube Jul 14, 2022

South Korea-based conglomerate Orion Holdings Corp. will enter China’s vaccine market by constructing a manufacturing...

Company Drug

Hangzhou DAC Biotech Doses First Patient in DXC007 AML Study

Fineline Cube Jul 14, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing in a...

Posts pagination

1 … 581 582 583 … 598

Recent updates

  • Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal
  • Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway
  • ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy
  • FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data
  • Sanofi’s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Company Medical Device

Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway

Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.